Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.65 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.65 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | CDK8 | P49336 | 7/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | AXL | P30530 | 2/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.44 |
| ▸ | PLK4 | O00444 | 2/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12338455 | 0.83 | FGFR1 (0.59) | KDRFGFR1BRD4CDK8MAPK1 | |
| SCHEMBL29652336 | 0.82 | BRD4 (0.62) | KDRFGFR1BRD4CDK8MAPK1 | |
| SCHEMBL413709 | 0.82 | KDR (0.54) | KDRFGFR1BRD4CDK8AXL | |
| SCHEMBL12127570 | 0.82 | BRD4 (0.65) | KDRFGFR1BRD4CDK8MAPK1 | |
| SCHEMBL415173 | 0.82 | KDR (0.54) | KDRFGFR1BRD4CDK8AXL | |
| SCHEMBL24896303 | 0.81 | CDK8 (0.50) | KDRFGFR1BRD4CDK8MAPK1 | |
| SCHEMBL22560747 | 0.81 | KDR (0.49) | KDRFGFR1BRD4CDK8MAPK1 | |
| SCHEMBL25067988 | 0.81 | KDR (0.49) | KDRFGFR1BRD4CDK8MAPK1 | |
| SCHEMBL4785921 | 0.80 | FGFR1 (0.59) | KDRFGFR1CDK8TNIKROCK2 | |
| SCHEMBL7993613 | 0.79 | FGFR1 (0.55) | KDRFGFR1BRD4CDK8MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 439 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110128422-B | Synthesis method of 5-methoxy-7-azaindole | 金凯(辽宁)生命科技股份有限公司 | 2022-03-18 | — | — | CN | claimed |
| EP-2292615-A1 | Quinazoline compounds | AstraZeneca AB (SE) | 2011-03-09 | — | — | EP | claimed |
| US-20090156821-A1 | Quinazoline compounds | ASTRAZENECA AB | 2009-06-18 | — | — | US | claimed |
| US-20050085465-A1 | Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents | ASTRAZENECA AB (SE) | 2005-04-21 | — | — | US | claimed |
| EP-1474420-A1 | QUINAZOLINE COMPOUNDS | Astrazeneca AB (SE) | 2004-11-10 | — | — | EP | claimed |
| WO-2003064413-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | WO | claimed |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | KULEON LLC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250388580-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFLECTION THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250367173-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LIGACHEM BIOSCIENCES INC (KR) | 2025-12-04 | — | — | US | disclosed |
| US-20250361233-A1 | Compounds For Activating Serotonin Receptor | Psylo Pty Ltd (AU) | 2025-11-27 | — | — | US | disclosed |
| US-20250340542-A1 | THYROID HORMONE RECEPTOR AGONISTS | INVENTISBIO CO LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| US-20250340513-A1 | NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS | KULEON LLC (US) | 2025-11-06 | — | — | US | disclosed |
| WO-2002016348-A1 | ANTIANGIOGENIC BICYCLIC DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002012228-A1 | CINNOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012226-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| EP-1092717-A2 | Polycyclic azaindole derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-04-18 | — | — | EP | disclosed |
| EP-0737685-B1 | Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 2000-07-19 | — | — | EP | disclosed |
| US-5714495-A | ANXIOLYTIC AGENTS, MELATONIN RECEPTORS FOR TREATING PSYCHOLOGICAL DISORDERS AND ANALGESICS, SLEEP DISORDERS | ADIR ET COMPAGNIE (FR) | 1998-02-03 | — | — | US | disclosed |
| EP-0737685-A1 | Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1996-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367173-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | ENPP1, ENPP3, SMPD1 | KDR 2912/4885FGFR1 3291/4885BRD4 2989/4885 |
| US-20250388580-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | POLR1C, PRKDC, MAPK1 | KDR 1757/4885FGFR1 181/4885BRD4 565/4885 |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | HTR2C, HTR7, HTR6 | KDR 2386/4885FGFR1 4063/4885BRD4 1293/4885 |
| US-20250361233-A1 | Compounds For Activating Serotonin Receptor | HTR2C, HTR2A, HTR6 | KDR 2568/4885FGFR1 3486/4885BRD4 3045/4885 |
| US-20250340542-A1 | THYROID HORMONE RECEPTOR AGONISTS | TSHR, THRA, TRHR | KDR 670/4885FGFR1 304/4885BRD4 1937/4885 |
| US-20050085465-A1 | Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents | VEGFA, FLT4, FLT1 | KDR 4/4885FGFR1 632/4885BRD4 69/4885 |
| US-20250340513-A1 | NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS | HTR2A, HTR2C, HTR3A | KDR 590/4885FGFR1 2754/4885BRD4 1798/4885 |
| US-20090156821-A1 | Quinazoline compounds | VEGFA, FLT4, FLT1 | KDR 5/4885FGFR1 1044/4885BRD4 93/4885 |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | SUB1, AHR, NCOA3 | KDR 1743/4885FGFR1 445/4885BRD4 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.